Related references
Note: Only part of the references are listed.Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
Walter Reinisch et al.
JOURNAL OF CROHNS & COLITIS (2021)
Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions
John Gubatan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers
Nishit B. Modi et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
Vitamin D Is Associated with α4β7+Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease
John Gubatan et al.
JOURNAL OF CROHNS & COLITIS (2021)
Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
Bram Verstockt et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects
Hiroyuki Fukase et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Parambir S. Dulai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program
William J. Sandborn et al.
ADVANCES IN THERAPY (2020)
Serum Interleukin-6 and-8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
Lorenzo Bertani et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Long-term safety of vedolizumab for inflammatory bowel disease
Edward V. Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE
Mark T. Osterman et al.
INFLAMMATORY BOWEL DISEASES (2019)
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases
Samuel J. S. Rubin et al.
NATURE COMMUNICATIONS (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
History of Inflammatory Bowel Diseases
Giovanni Clemente Actis et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2019)
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig et al.
GUT (2019)
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Toshifumi Hibi et al.
INTESTINAL RESEARCH (2019)
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+T Cells in Crohn's Disease: Report of the TOSCA Study
Geert D'Haens et al.
JOURNAL OF CROHNS & COLITIS (2018)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease
Christopher A. Lamb et al.
JOURNAL OF CROHNS & COLITIS (2018)
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Sudarshan Paramsothy et al.
MUCOSAL IMMUNOLOGY (2018)
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
S. Tadbiri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study
William J. Sandborn et al.
GUT (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
W.J. Sandborn et al.
Journal of Crohns & Colitis (2017)
P113 Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients
L. Mattheakis et al.
Journal of Crohns & Colitis (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Pei-Ran Ho et al.
LANCET NEUROLOGY (2017)
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
Katrina M. de lange et al.
NATURE GENETICS (2017)
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy
Heitor S. P. de Souza et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Friederike Fuchs et al.
FRONTIERS IN IMMUNOLOGY (2017)
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
A. Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases
Ashwin N. Ananthakrishnan et al.
CELL HOST & MICROBE (2017)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Aurelien Amiot et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
Gaik W. Tew et al.
GASTROENTEROLOGY (2016)
Leukocyte Trafficking to the Small Intestine and Colon
Aida Habtezion et al.
GASTROENTEROLOGY (2016)
A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures
Michael Thomas Wong et al.
IMMUNITY (2016)
PTG-100, An Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models
Larry Mattheakis et al.
INFLAMMATORY BOWEL DISEASES (2016)
Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease
Benjamin Click et al.
INFLAMMATORY BOWEL DISEASES (2016)
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes
Gionata Fiorino et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy
Emanuelle Bellaguarda et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
Naoki Yoshimura et al.
GASTROENTEROLOGY (2015)
Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases
Wei-Jian Pan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
Pharmacology of AMG 181, a human anti-α4β7 antibody that specifically alters trafficking of gut-homing T cells
W. J. Pan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
In vitro Culture of Tumour-Derived Hepatocytes in Decellularised Whole-Liver Biological Scaffolds
Yuan Cheng et al.
DIGESTION (2013)
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Paul J. Rutgeerts et al.
GUT (2013)
Natalizumab in Crohn's Disease: Results From a US Tertiary Inflammatory Bowel Disease Center
Atsushi Sakuraba et al.
INFLAMMATORY BOWEL DISEASES (2013)
Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice
Toshihiko Sugiura et al.
Journal of Crohns & Colitis (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience
S. V. Kane et al.
INFLAMMATORY BOWEL DISEASES (2012)
The final steps of integrin activation: the end game
Sanford J. Shattil et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
N. Pullen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial
Masakazu Takazoe et al.
GASTROENTEROLOGY (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intracellular signalling controlling integrin activation in lymphocytes
T Kinashi
NATURE REVIEWS IMMUNOLOGY (2005)
An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin αLβ2
G Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
FH Gordon et al.
GASTROENTEROLOGY (2001)
VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice
A Soriano et al.
LABORATORY INVESTIGATION (2000)
Share Paper
